![]() Father with ADHD says uncertain months ahead 'frightening' "I think it's really important … they need to understand the effects that it's having on people in Australia and New Zealand, and we're certainly very willing to work with them," said its president, Dr Moore. The Royal Australian and New Zealand College of Psychiatrists is still waiting for the DEA to respond to its request for an urgent meeting. "Takeda understands the importance of maintaining consistent treatment with Vyvanse … and have communicated with the DEA regarding global prescription volumes for Vyvanse as part of the normal quota process." "We are working to resolve these interruptions as quickly as possible and expect normal supply of impacted strengths to resume between March and April 2024. "Takeda utilised its full DEA-allotted lisdexamfetamine quota for 20 production," a spokesman told the ABC. "We've written to the DEA to seek advice from them as to whether or not they can in fact increase the amount that is coming to Australia and New Zealand," Dr Moore said.īut the only company which brings Vyvanse into Australia, Takeda Pharmaceuticals, revealed it has been manufacturing at full capacity. The president of the college, Dr Elizabeth Moore, said the DEA controlled how much Vyvanse was allotted to Australia and New Zealand. The severe shortage of Vyvanse prompted multiple Australian groups to write to the US DEA, pleading with the officials to lift production limits of lisdexamfetamine to ease the pressure on patients.Ī letter obtained by the ABC also reveals that late last year, the Royal Australian and New Zealand College of Psychiatrists asked for an urgent meeting with the administration in the hopes of shoring up medication supply. In Australia, buying generic lisdexamfetamine medication is not available because Takeda Pharmaceuticals still owns Vyvanse under patent. Lisdexamfetamine is made in the United States and is tightly controlled because of its potential for abuse, with the Drug Enforcement Administration (DEA) setting limits on how much the industry can make. ![]() The shortage is further complicated because Vyvanse contains an active ingredient called lisdexamfetamine. Since then, the situation has worsened, with the Therapeutic Goods Administration advising Australians there are now four different strengths in shortage - 30mg, 40mg, 50mg and 60mg. The drug Vyvanse is used to treat adults and children with Attention-Deficit/Hyperactivity Disorder (ADHD) but from August last year, patients on certain strengths of the medication have struggled to fill prescriptions. The only pharmaceutical company in Australia which supplies a critical ADHD drug in the grips of a global shortage will not be allowed to ramp up production after US drug officials, who control the key ingredient, refused to raise manufacturing limits.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |